Начало › Тройно негативен рак на гърдата › Тексас › Houston
Клинични проучвания за Тройно негативен рак на гърдата в Houston, TX
42 проучвания за Тройно негативен рак на гърдата търсят участници в обекти в и около Houston (в радиус от около 30 мили). Отворете проучването, за да видите кой може да участва и как да се свържете с екипа.
Официален текст на проучването (английски)
Търсите участници за проучване? Представяме го в началото на тази страница — $99 за 30 дни →
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Набиране на участнициФаза 1
- University of Texas MD Anderson Cancer Center, Houston
- NEXT Houston, Houston
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Набиране на участнициФаза 1
- University of Texas MD Anderson Cancer Center, Houston
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Набиране на участнициФаза 1/2
- The University of Texas MD Anderson Cancer Center, Houston
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Набиране на участнициФаза 1/2
- MD Anderson Cancer Center, Houston
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
Набиране на участнициФаза 1/2
- MD Anderson Cancer Center, Houston
Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
Набиране на участници
- M D Anderson Cancer Center, Houston
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Набиране на участнициФаза 3
- Kelsey-Seybold Clinic - North Houston Campus ( Site 0096), Houston
- Kelsey-Seybold Clinic ( Site 0040), Houston
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Набиране на участнициФаза 3
- Oncology Consultants P.A. ( Site 0107), Houston
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Набиране на участнициФаза 3
- Kelsey-Seybold Clinic ( Site 0042), Houston
- Kelsey-Seybold Clinic ( Site 0088), Houston
- Oncology Consultants P.A. ( Site 0073), Houston
Intratumoral N17350 in Advanced Solid Tumors
Набиране на участнициФаза 1/2
- The University of Texas MD Anderson Cancer Center, Houston
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Набиране на участнициФаза 1
- Oncology Consultants, P.A., Houston
- University of Texas M.D. Anderson Cancer Center, Houston
A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
Набиране на участнициФаза 1
- The University of Texas MD Anderson Cancer Center, Houston
Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
Набиране на участнициФаза 2
- Baylor College of Medicine, Houston
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
Набиране на участнициФаза 1
- MD Anderson Cancer Center, Houston
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Набиране на участнициФаза 3
- MD Anderson Cancer Center, Houston
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Набиране на участнициФаза 1
- The University of Texas - MD Anderson Cancer Center, Houston
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
Набиране на участнициНаблюдателно проучване
- UT Health Houston, Houston
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
Набиране на участнициФаза 1
- MD Anderson Cancer Center, Houston
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Набиране на участнициФаза 1/2
- Research Site, Houston
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Набиране на участнициФаза 1
- Normunity Investigational Site, Houston
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Набиране на участнициФаза 1/2
- Houston Methodist Hospital, Houston
SMP-3124LP in Adults With Advanced Solid Tumors
Набиране на участнициФаза 1/2
- MD Anderson Cancer Center, Houston
Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer
Набиране на участнициФаза 1
- UT MD Anderson Cancer Center, Houston
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Набиране на участнициФаза 2/3
- (USOR) Texas Oncology, Houston
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Набиране на участнициФаза 1
- Uni Of TX MD Anderson Cancer Cntr, Houston
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Набиране на участнициФаза 1
- The University of Texas MD Anderson Cancer Center Investigational Pharmacy Services, Houston
- The University of Texas MD Anderson Cancer Center, Houston
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
Набиране на участнициФаза 1
- The University of Texas - M.D. Anderson Cancer Center, Houston
- The University of Texas, MD Anderson Cancer Center - West Houston, Houston
Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)
Набиране на участнициФаза 1/2
- The University of Texas M. D. Anderson Cancer Center, Houston
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Набиране на участнициФаза 1/2
- MD Anderson, Houston
A Study of LY4175408 in Participants With Advanced Cancer
Набиране на участнициФаза 1
- MD Anderson Cancer Center, Houston
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Набиране на участнициФаза 1
- The University of Texas MD Anderson Cancer Center /ID# 270059, Houston
Study of XB010 in Subjects With Solid Tumors
Набиране на участнициФаза 1
- University of Texas MD Anderson Cancer Center, Houston
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
Набиране на участнициФаза 1
- MD Anderson, Houston
- NEXT Texas LLC - Houston, Houston
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
Набиране на участнициФаза 1
- The University of Texas MD Anderson Cancer Center, Houston
Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)
Набиране на участнициФаза 2
- Houston Methodist Neal Cancer Center, Houston
- The University of Texas MD Anderson Cancer Center, Houston
Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer
Набиране на участнициФаза 2
- MD Anderson Cancer Center, Houston
PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer
Набиране на участнициФаза 1
- MD Anderson Cancer Center, Houston
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
Набиране на участнициФаза 1/2
- M.D. Anderson Cancer Center, Houston
Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
Набиране на участнициФаза 1/2
- The University of Texas MD Anderson Cancer Center, Houston
A Study of NX-1607 in Adults With Advanced Malignancies
Набиране на участнициФаза 1
- MD Anderson Cancer Center, Houston
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
Набиране на участнициФаза 2
- Harris Health System - Smith Clinic, Houston
- O'Quinn Medical Tower - McNair Campus - Dan L Duncan Comprehensive Cancer Center, Houston
CtDNA Based MRD Testing for NAC Monitoring in TNBC
Набиране на участнициНаблюдателно проучване
- The University of Texas MD Anderson Cancer Center, Houston
Проучвания за Тройно негативен рак на гърдата в други градове
- New York City, NY31 проучвания
- Nashville, TN28 проучвания
- Los Angeles, CA27 проучвания
- Boston, MA26 проучвания
- San Antonio, TX23 проучвания
- St. Louis, MO21 проучвания
- Arlington, VA20 проучвания
- Atlanta, GA20 проучвания
- Dallas, TX18 проучвания
- Chicago, IL16 проучвания
- Columbus, OH16 проучвания
- Grand Rapids, MI15 проучвания
Други проучвания в Houston
- Рак на белия дроб с недребноклетъчен тип145 проучвания
- Рак на гърдата126 проучвания
- Рак (всички видове)121 проучвания
- Метастатичен рак104 проучвания
- Колоректален рак102 проучвания
- Рак на яйчниците89 проучвания
- Остра миелоидна левкемия85 проучвания
- Рак на белия дроб78 проучвания
- Рак на простатата76 проучвания
- Ендометриален рак68 проучвания
- Рак на панкреаса61 проучвания
- Меланом59 проучвания
От ClinicalTrials.gov, данни към 6.10.2026 г.. Всяко проучване има свои критерии за участие; екипът на проучването определя кой може да се включи.